Nykredit Realkredit A/S
To Nasdaq Copenhagen
17 March 2021
CORRECTION Nykredit Realkredit A/S – New final terms for Euro Medium Term Note Programme
Nykredit Realkredit A/S publishes final terms for an issue of EUR 50,000,000 0.01% Senior Non-Preferred Notes due 2024, which are issued pursuant to Nykredit Realkredit A/S's and Nykredit Bank A/S’s €10,000,000,000 Euro Medium Term Note Programme dated 13 May 2020.
The final terms dated 17 March 2021 and the EMTN Programme dated 13 May 2020 are available for download on Nykredit's website at nykredit.com/ir.
A previous version of this announcement incorrectly contained the words "Floating Rate" rate in the title of the Final Terms.
Enquiries may be addressed to Nykredit Realkredit A/S, Nicolaj Verdelin, Head of Funding Trading, Funding & Capital, tel +45 44 55 11 25, or Morten Bækmand Niel-sen, Head of Investor Relations, tel +45 44 55 15 21.
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Novartis Pharma AG19.10.2025 16:30:00 CEST | Press release
PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer
Genmab A/S18.10.2025 12:00:34 CEST | Press release
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
F. Hoffmann-La Roche Ltd18.10.2025 07:00:00 CEST | Press release
Roche’s phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer
StoneX Group Inc.18.10.2025 01:12:36 CEST | Press release
StoneX Expands Wealth Management Offering for Latin American Clients
F. Hoffmann-La Roche Ltd17.10.2025 22:20:00 CEST | Press release
Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom